Madrigal Pharmaceuticals (MDGL) Share-based Compensation (2010 - 2026)

Madrigal Pharmaceuticals (MDGL) has 17 years of Share-based Compensation data on file, last reported at $34.0 million in Q1 2026.

• On a quarterly basis, Share-based Compensation rose 62.52% year-over-year to $34.0 million in Q1 2026; TTM through Mar 2026 was $17.1 million, a 602.72% increase from a year earlier, with the FY2025 full-year figure at $4.0 million, up 206.31% from the prior year.
• Share-based Compensation for Q1 2026 stood at $34.0 million, up from -$68.4 million in the prior quarter.
• Over the last five years, Share-based Compensation for MDGL reached as high as $68.4 million in Q3 2025 and fell as low as -$68.4 million in Q4 2025.
• Historically, Share-based Compensation has averaged $2.8 million across 5 years, with a median of $1.2 million in 2024.
• On a YoY basis, Share-based Compensation climbed as much as 5596.67% in 2025 and fell as far as 34280.0% in 2025.
• Year by year, Share-based Compensation stood at -$6.9 million in 2022, then soared by 99.59% to -$28000.0 in 2023, then jumped by 814.29% to $200000.0 in 2024, then plunged by 34280.0% to -$68.4 million in 2025, then soared by 149.76% to $34.0 million in 2026.
• Per Business Quant data, the three most recent Share-based Compensation figures were $34.0 million in Q1 2026, -$68.4 million in Q4 2025, and $68.4 million in Q3 2025.